Therefore, immunotherapy in combination with the anti-VEGFR-2 drugs, such as the drugs mentioned above (sorafenib, lenvatinib, regorafenib, cabozantinib, sunitinib, linifanib, and brivanib), is another new promising direction in the treatment of HCC. Here, KDR is linked to hepatocellular carcinoma.